|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Current assets: | |||||||||
| Cash | |||||||||
| Deferred offering costs | |||||||||
| Prepaid expenses | |||||||||
| Total current assets | |||||||||
| Cash held in Trust Account | |||||||||
| Investments held in Trust Account | |||||||||
| Total assets | |||||||||
| Liabilities and shareholders' deficit | |||||||||
| Current liabilities: | |||||||||
| Accrued formation and offering costs | |||||||||
| Accrued expenses, formation and offering costs | |||||||||
| Accrued professional fees and other expenses | |||||||||
| Note payable to Sponsor | |||||||||
| Derivative liabilities | |||||||||
| Deferred underwriting compensation | |||||||||
| Total current liabilities | |||||||||
| Deferred underwriting compensation | |||||||||
| Total liabilities | |||||||||
| Class A ordinary shares subject to possible redemption; 25,000,000 shares as of June 30, 2023 and December 31, 2022 at a redemption value of $10.37 and $10.15 per share, respectively | |||||||||
| Shareholders' deficit: | |||||||||
| Common shares, value | |||||||||
| Additional paid-in capital | |||||||||
| Accumulated deficit | |||||||||
| Class F Ordinary Shares | |||||||||
| Total shareholders' deficit | |||||||||
| Total liabilities and shareholders' deficit |
Loading...
